IP Library Granted Patent US 11,970,693
Granted Patent B2
US 11,970,693 · App. 16/791,456 · Granted Apr 30, 2024

Methods of selecting binding reagents

Inventor: Parag Mallick (San Mateo, CA)
Assignee: NAUTILUS SUBSIDIARY, INC.
C12N15/1055G01N33/6845
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,970,693
App. No.
16/791,456
Granted
Apr 30, 2024
Kind
B2
Abstract

Methods and systems are provided herein for selecting an affinity reagent which binds a desired peptide epitope in a plurality of sequence contexts. The method relies on obtaining a peptide library, each peptide having the sequence αXβ, wherein X is the desired peptide epitope, wherein each of α and β comprise an amino acid, using the peptide library to select an affinity reagent.

Claims (33)

1. A method for selecting an affinity reagent which binds a desired peptide epitope in a plurality of sequence contexts, the method comprising:

obtaining a peptide library comprising a plurality of at least 400 sequence contexts, each peptide of the peptide library comprising the sequence αXβ, wherein X is the desired peptide epitope, wherein X is a sequence of 2, 3 or 4 amino acids, wherein each of a and comprises at least one amino acid, and wherein each of α and β varies amongst the plurality of sequence contexts within the peptide library; and

screening one or more affinity reagents against the peptide library to select an affinity reagent from among the one or more affinity reagents which binds the desired peptide epitope X in at least 10% of the plurality of sequence contexts, wherein the selected affinity reagent is selected from the group consisting of an antibody, an aptamer, a peptamer, and an antibody fragment.

2. The method of claim 1 , wherein each of α and β consists of one amino acid.

3. The method of claim 1 , wherein at least one of α and β further comprises a linker.

4. The method of claim 1 , wherein at least one of α and β further comprises a modification selected from the group consisting of a N-terminal modification, a C-terminal modification, a positively-charged group, a negatively-charged group, a hydrophobic group, and a sugar.

5. The method of claim 1 , wherein each of α and β consists of between one and three amino acids.

6. The method of claim 1 , wherein the selected affinity reagent is the antibody.

7. The method of claim 1 , further comprising:

Characterizing the binding of the selected affinity reagent by screening the selected affinity reagent against a plurality of peptides of the same length of the desired epitope.

8. The method of claim 7 , wherein the plurality of peptides of the same length of the desired epitope is representative of at least 90% of all possible variations of peptides of the same length of the desired epitope.

9. The method of claim 1 , further comprising:

characterizing the binding of the selected affinity reagent by screening the selected affinity reagent against a plurality of peptides, wherein each peptide of the plurality of peptides comprises the desired epitope and one or more flanking residues.

10. The method of claim 7 , further comprising:

characterizing the binding of the selected affinity reagent by screening the selected affinity reagent against a second plurality of peptides, wherein each peptide of the plurality of peptides comprises a secondary epitope and one or more flanking residues.

11. The method of claim 1 , further comprising:

characterizing the binding of the selected affinity reagent at least in part by screening the selected affinity reagent against a plurality of subsets of a plurality of peptides shorter than the desired peptide epitope.

12. The method of claim 1 , further comprising characterizing the selected affinity reagent by screening the selected affinity reagent against a panel of proteins or peptides which contain the desired epitope.

13. The method of claim 1 , wherein the selected affinity reagent binds to at least 20% of the plurality of sequence contexts.

14. The method of claim 1 , further comprising characterizing the selected affinity reagent by screening the selected affinity reagent against a panel of proteins which do not contain the X epitope.

15. The method of claim 1 , wherein the selected affinity reagent binds to at least 30% of the plurality of sequence contexts.

16. The method of claim 1 , wherein the selected affinity reagent is screened against a library of random peptides having a length between 2 and 10 amino acids, and further comprising:

identifying the peptides bound by the selected affinity reagent; and

retaining the selected affinity reagent if 1) it binds less than twenty different epitopes and 2) it binds at least 10% of all peptides longer than 5 amino acids containing that epitope.

17. The method of claim 16 , wherein the selected affinity reagent binds at least 15% of all peptides longer than 5 amino acids containing the epitope.

18. The method of claim 1 , further comprising:

characterizing the binding of the affinity reagent by screening the affinity reagent against a library of peptides, the library of peptides comprising peptides shorter than the desired epitope, peptides of the same length of the desired epitope, and peptides longer than the desired epitope; and

identifying the sequences of bound peptides, thereby characterizing the binding of the affinity reagent.

19. The method of claim 1 , wherein the selected affinity reagent is the aptamer.

20. The method of claim 1 , wherein the selected affinity reagent is the peptamer.

21. The method of claim 1 , wherein the selected affinity reagent is the antibody fragment.

22. The method of claim 1 , wherein the peptide library is used in a denatured state to select said affinity reagent.

23. The method of claim 1 , further comprising retaining the selected affinity reagent for further screening.

Assignments (2)
CHANGE OF NAME Recorded Apr 21, 2023
From: NAUTILUS BIOTECHNOLOGY, INC.
To: NAUTILUS SUBSIDIARY, INC.
Reel/Frame 063439/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2020
From: MALLICK, PARAG; EGERTSON, JARRETT D.
To: NAUTILUS BIOTECHNOLOGY, INC.
Reel/Frame 052584/0427 →
Continuity (3)
Continuation PCTUS2018000364 · Aug 20, 2018
Provisional Application 62547699 · Aug 18, 2017
Related Publication 20200318101A1 · Oct 8, 2020
Cited By (2)
US 12,577,608 US 12,612,621